Page 62 - Read Online

Page 130 Constantinides et al. Neuroimmunol Neuroinflammation 2020;7:120-31 I http://dx.doi.org/10.20517/2347-8659.2019.22

23. Urakami K, Wada K, Arai H, Sasaki H, Kanai M, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with
corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183:95-8.
24. Borroni B, Premi E, Agosti C, Alberici A, Cerini C, et al. CSF Alzheimer’s disease-like pattern in corticobasal syndrome: evidence for a
distinct disorder. J Neurol Neurosurg Psychiatry 2011;82:834-8.
25. Constantinides VC, Paraskevas GP, Efthymiopoulou E, Stefanis L, Kapaki E. Clinical, neuropsychological and imaging characteristics of
Alzheimer’s disease patients presenting as corticobasal syndrome. J Neurol Sci 2019;398:142-7.
26. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and
progression. Ann Neurol 2011;69:570-80.
27. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, et al. alpha-Synuclein and tau concentrations in
cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-40.
28. Abdo WF, van de Warrenburg BP, Kremer HP, Bloem BR, Verbeek MM. CSF biomarker profiles do not differentiate between the
cerebellar and parkinsonian phenotypes of multiple system atrophy. Parkinsonism Relat Disord 2007;13:480-2.
29. Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RA, et al. CSF neurofilament light chain but not FLT3 ligand discriminates
parkinsonian disorders. Front Neurol 2015;6:91.
30. Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy
from Parkinson’s disease. Mov Disord 2004;19:571-9.
31. Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD
patients and controls. Parkinsonism Relat Disord 2014;20:112-5.
32. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid
of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005;19:164-70.
33. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, et al. Total tau protein, phosphorylated tau (181p) protein, beta-
amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med
2006;44:192-5.
34. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, et al. Cerebrospinal fluid levels of sappalpha and sappbeta in lewy body and
Alzheimer’s disease: clinical and neurochemical correlates. Int J Alzheimers Dis 2011;2011:495025.
35. Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, et al. Cerebrospinal alpha-synuclein in alpha-synuclein aggregation disorders:
tau/alpha-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol 2016;263:2271-7.
36. van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Amyloid-beta peptides in cerebrospinal fluid of patients
with dementia with Lewy bodies. Alzheimers Res Ther 2019;11:83.
37. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, et al. Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia
and dementia with Lewy bodies. Biol Psychiatry 2008;64:850-5.
38. Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, et al. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia
with Lewy bodies, Parkinson’s disease, and Alzheimer’s disease. J Alzheimers Dis 2014;38:63-73.
39. Gmitterova K, Gawinecka J, Llorens F, Varges D, Valkovic P, et al. Cerebrospinal fluid markers analysis in the differential diagnosis of
dementia with Lewy bodies and Parkinson’s disease dementia. Eur Arch Psychiatry Clin Neurosci 2018.
40. Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, et al. Cerebrospinal fluid markers in dementia with lewy bodies compared
with Alzheimer disease. Arch Neurol 2003;60:1218-22.
41. Boström F, Hansson O, Blennow K, Gerhardsson L, Lundh T, et al. Cerebrospinal fluid total tau is associated with shorter survival in
dementia with Lewy bodies. Dement Geriatr Cogn Disord 2009;28:314-9.
42. Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, et al. Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive
decline in lewy body dementia. Mov Disord 2016;31:1203-8.
43. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau:
marker candidates for dementia with lewy bodies. Neurodegener Dis 2007;4:366-75.
44. Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, et al. Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in
dementia with lewy bodies. J Alzheimers Dis 2013;35:137-46.
45. van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, et al. Cerebrospinal fluid Alzheimer’s disease biomarkers across the
spectrum of lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis 2016;54:287-95.
46. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, et al. Follow-up investigations in cerebrospinal fluid of patients with
dementia with Lewy bodies and Alzheimer’s disease. J Neural Transm (Vienna) 2005;112:933-48.
47. Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, et al. Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau,
Abeta42, and Abeta40) in prodromal stage of Alzheimer’s disease and dementia with lewy bodies. J Alzheimers Dis 2016;51:1069-83.
48. Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, et al. Cerebrospinal fluid Alzheimer biomarkers can be useful for
discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage. J Neurol Neurosurg Psychiatry 2018;89:467-75.
49. Paraskevas GP, Bougea A, Constantinides VC, Bourbouli M, Petropoulou O, et al. In vivo prevalence of Alzheimer biomarkers in
dementia with lewy bodies. Dement Geriatr Cogn Disord 2019;47:289-96.
50. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, et al. beta-amyloid peptides enhance alpha-synuclein accumulation
and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease. Proc Natl Acad Sci U S A
2001;98:12245-50.
51. Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, et al. Pathological interface between
oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry 2015;78:672-83.